Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. We included patients t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2019-07, Vol.81 (1), p.143-151
Main Authors: Faiz, Sarah, Giovannelli, Jonathan, Podevin, Céline, Jachiet, Marie, Bouaziz, Jean-David, Reguiai, Ziad, Nosbaum, Audrey, Lasek, Audrey, Ferrier le Bouedec, Marie-Christine, Du Thanh, Aurélie, Raison-Peyron, Nadia, Tetart, Florence, Duval-Modeste, Anne-Bénédicte, Misery, Laurent, Aubin, François, Dompmartin, Anne, Morice, Cécile, Droitcourt, Catherine, Soria, Angèle, Arnault, Jean-Philippe, Delaunay, Juliette, Mahé, Emmanuel, Richard, Marie-Aleth, Schoeffler, Amélie, Lacour, Jean-Philippe, Begon, Edouard, Walter-Lepage, Amélie, Dillies, Anne-Sophie, Rappelle-Duruy, Sandrine, Barete, Stéphane, Bellon, Nathalia, Bénéton, Nathalie, Valois, Aude, Barbarot, Sébastien, Sénéchal, Julien, Staumont-Sallé, Delphine
Format: Article
Language:English
Subjects:
adults
atopic dermatitis
biotherapy
conjunctivitis
dupilumab
eosinophilia
Life Sciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P 
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2019.02.053